Startups
Delivering innovative medicines to patients where no others have proven effective or existed.
Overview
Location
United States, California, Carlsbad
Phone
+1 760-931-9200
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 27, 2026 | AstraZeneca Q2 Earnings Beat Analysts as Cancer Drugs Carry $80B Target | By Jerry Owens Published: Jul 27 2026, 10:32 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 15, 2026 | Tau Therapy Slows Alzheimer’s Decline in First Human Trial as AAIC 2026 Wraps in London | By Ronald Holman Published: Jul 15 2026, 11:50 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 14, 2026 | Alzheimer’s Tau Drug Slows Cognitive Decline and Cuts Brain Tangles in Trial | By Russell White Published: Jul 14 2026, 4:14 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 12, 2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| Jul 9, 2026 | Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback | By John Bright Published: Jul 09 2026, 11:18 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 9, 2026 | AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse | AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition. Shares slumped and were on track for the worst day in over six years. Jefferies analysts s... |
| May 26, 2026 | New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia | New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia Tue, May 26, 2026 16:15 CET Report this content Sobi® (STO: SOBI) today announced results from a new analysi... |
| Sep 19, 2025 | Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) | Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) Fri, Sep 19, 2025 08:00 CET Report this content Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative trea... |
| Aug 1, 2025 | The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary | Share Share Share Share Email The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary. This premier global ga... |
Show more
Reviews 0
FAQ about Ionis Pharmaceuticals
What has the press written about Ionis Pharmaceuticals?
Parsers VC has collected 12 articles mentioning Ionis Pharmaceuticals, among them “AstraZeneca Q2 Earnings Beat Analysts as Cancer Drugs Carry $80B Target” (Jul 27, 2026) and “Tau Therapy Slows Alzheimer’s Decline in First Human Trial as AAIC 2026 Wraps in London” (Jul 15, 2026).
Is Ionis Pharmaceuticals still active?
Yes, Ionis Pharmaceuticals is active; its latest activity on Parsers VC dates from Aug 9, 2026.